Delving into the Latest Updates on SA-ANP with Synapse

Overview

Basic Info

Drug Type

Biological products

Synonyms

mANP

Target

Aldosterone

Mechanism

Aldosterone antagonists

Therapeutic Areas

Cardiovascular DiseasesUrogenital Diseases

Active Indication

Resistant hypertensionChronic Kidney DiseasesHeart failure with normal ejection fraction

Inactive Indication-

Originator Organization

Mayo Clinic

Active Organization

Mayo Clinic

Inactive Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

This is a Phase 2 dose-titration study designed to evaluate the safety and efficacy of MANP subcutaneous injection compared to placebo in reducing baseline daytime systolic blood pressure (SBP), derived from 24-hour ambulatory blood pressure monitoring (ABPM), in subjects with hypertension who are taking 3 or more antihypertensive medications with different mechanisms of action.

Start Date01 Nov 2024

Sponsor / Collaborator

E-Star BioTech, LLC

[+3]

NCT05279742 / Enrolling by invitationPhase 1/2IIT

Enhancing the Natriuretic Peptide System in HFpEF: a Randomized Double-Blind Placebo-Controlled Triple Crossover Study

The purpose of this study is to look at the differences in how individuals with heart failure with preserved ejection fraction in the presence of chronic kidney disease (HFpEF-CKD) and exercise induced dyspnea without objective findings of fluid retention (HFpEF-EI) bodies function using drugs Sacubatril/Valsartan (Entresto) and MANP.

Start Date04 Nov 2022

Sponsor / Collaborator

Mayo Clinic

NCT05247528 / CompletedPhase 1

A Phase 1B, Multiple Ascending Dose Trial Examining The Safety And Tolerability Of Subcutaneous MANP In Difficult To Control/Resistant Hypertensive Subjects

A randomized, double-blind, placebo-controlled multiple ascending dose study in hypertensive subjects on stable doses of at least three hypertensive drugs for at least 6 weeks prior to Screening. The study will consist of screening, PK-unit admittance, and safety follow up periods.
Subjects will be randomized at a 6:2 ratio of either MANP or placebo and will be stratified by race in each dosage cohort. The entire first Cohort will be given the lowest dosage with subsequent cohorts progressing sequentially to the higher doses depending on safety and tolerability of the previous cohort.
Endpoints not related to the safety reviews will be analyzed after the last patient last visit (LPLV).

Start Date20 Dec 2021

Sponsor / Collaborator

E-Star BioTech, LLC

[+2]

100 Clinical Results associated with SA-ANP

Login to view more data

100 Translational Medicine associated with SA-ANP

Login to view more data

100 Patents (Medical) associated with SA-ANP

Login to view more data

54

Literatures (Medical) associated with SA-ANP

01 Dec 2024·Regenerative Therapy

Multifunctional type lll recombinant human collagen incorporated sodium alginate hydrogel with sustained release of extra cellular vehicles for wound healing multimodal therapy in diabetic mice

Article

Author: Jia, Yao ; Yan, Xin ; Zhang, Yue ; Zhang, Baolin ; Han, Yaxi ; Li, Lei

The effective promotion of wound healing poses a substantial challenge for clinical treatment. Despite evidence supporting the role of extracellular vesicles (EVs) in this process, their therapeutic potential is currently restrict by challenges in targeting and maintaining them. The manufacturing process for rhCol III, or recombinant human collagen III, is stable, and the rejection rate is low. We used a cross-linking method to prepare a rhCol III incorporated sodium alginate (SA) hydrogel, which enabled to accomplish an EV sustained release that was site-specific. Cell viability through MTT assay, proliferation and ROS generation were performed with MC3T3-E1cell lines. In addition, diabetic wounds are characterised by an environment of hyper-inflammation and elevated oxidative stress. The rhCol III/SA-EVs hydrogel, which is a delivery vehicle with anti-inflammatory and antioxidant characteristics, promotes wound healing in this setting. The In vivo effectiveness of the created wound dressing on a diabetic wound model was examined in this study. After 21 days of treatment, the wound dressing significantly (p < 0.05) expedited wound healing compared to the control group, and wound closure was approximately 95% without any negative systemic reactions.

01 Apr 2024·Colloids and Surfaces B: Biointerfaces

The investigation on sialic acid-modified pectin nanoparticles loaded with oxymatrine for orally targeting and inhibiting the of ulcerative colitis

Article

Author: Fan, Mengyao ; Sun, Changshan ; Zhao, Chunying ; Yang, Xin ; Sun, Tongtong ; Jiang, Tongying ; Tian, Linan

The aim of the study was to develop an oral targeting drug delivery system (OTDDS) of oxymatrine (OMT) to effectively treat ulcerative colitis (UC). The OTDDS of OMT (OMT/SA-NPs) was constructed with OMT, pectin, Ca²⁺, chitosan (CS) and sialic acid (SA). The obtained particles were characterized in terms of particle size, zeta potential, morphology, drug loading, encapsulation efficiency, drug release and stability. The average size of OMT/SA-NPs was 255.0 nm with a zeta potential of -12.4 mV. The loading content and encapsulation efficiency of OMT/SA-NPs were 14.65% and 84.83%, respectively. The particle size of OMT/SA-NPs changed slightly in the gastrointestinal tract. The nanoparticles can delivery most of the drug to the colon region. In vitro cell experiments showed that the SA-NPs had excellent biocompatibility and anti-inflammation, and the uptake of SA-NPs by RAW 264.7 cells was time and concentration-dependent. The conjugated SA can help the internalization of NPs into target cells. In vivo experiments showed that OMT/SA-NPs had a superior anti-inflammation effect and the effect of reducing UC, which was attributed to the delivery most of OMT to the colonic lumen, the specific targeting and retention in colitis site and the combined anti-inflammation of OMT and NPs.

01 Feb 2024·Colloids and Surfaces B: Biointerfaces

APTES-mediated Cu2(OH)3(NO3) nanomaterials on the surface of silicone catheters for abscess

Article

Author: Wu, Yayun ; Fu, Wanyue ; Jiang, Yechun ; Liu, Lin ; Shao, Min ; Chu, Zhaoyou ; Ye, Haoming ; Qian, Haisheng ; Li, Jun ; Fang, Ming ; Liu, Nian

Metal-based nanomaterials have remarkable bactericidal effects; however, their toxicity cannot be disregarded. To address this concern, we developed a simple synthesis route for antibacterial catheters using metal-based nanomaterials to reduce toxicity while harnessing their excellent bactericidal properties. The grafting agent (3-aminopropyl)triethoxysilane (APTES) forms -NH₂ groups on the catheter surface, onto which copper ions form a nanomaterial complex known as Cu₂(OH)₃(NO₃) (defined as SA-Cu). The synthesized SA-Cu exhibited outstanding contact antibacterial effects, as observed through scanning electron microscopy (SEM), which revealed cell membrane crumbing and bacterial rupture on the catheter surface. Furthermore, SA-Cu exhibited excellent biosafety characteristics, as evidenced by the cell counting kit-8 (CCK-8) assay, which showed no significant cytotoxicity. SA-Cu demonstrated sustained antimicrobial capacity, with in vivo experiments demonstrating over 99% bactericidal efficacy against methicillin-resistant Staphylococcus aureus (MRSA) for two weeks. The transcriptome sequencing results suggested that SA-Cu may exert its bactericidal effects by interfering with histidine and purine metabolism in MRSA. This study presents a straightforward method for synthesizing antimicrobial silicone catheters containing copper nanomaterials using copper ions.

100 Deals associated with SA-ANP

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Resistant hypertension	Phase 2	US	Mayo Clinic	01 Nov 2024
Chronic Kidney Diseases	Phase 2	US	Mayo Clinic	04 Nov 2022
Heart failure with normal ejection fraction	Phase 2	US	Mayo Clinic	04 Nov 2022

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


phase 1B clinical trial (ESC2024)	Phase 1	Resistant hypertension	36	MANP	ldjvnepwea(qjkmwrclxd) = There were no reported drug related serious adverse events opylpgmpzt (neuxybcrqa ) View more	Positive	30 Aug 2024
				Placebo
NCT03781739 (ESC2023)	Phase 1	Metabolic Syndrome \| Hypertension	22	MANP	sixzrunrcy(racsgftwau) = lbockxpgwp enyehfiobo (xfltngmcgc ) View more	-	26 Aug 2023
ESC2016	Phase 1	Hypertension	-	ZD100	veliudwabn(sghdkamjhu) = ouqfffzltx ykdudgjewi (dxhisaizfg ) View more	-	28 Aug 2016
				Placebo	bkhmwcohzl(cklmlsewvq) = adyitgoxgh ozksbowcib (nfzxqgegxw ) View more